{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:24:14Z","timestamp":1792686254009,"version":"4.5.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Lymphocytic thyroiditis (LT) is frequently seen in the tumor microenvironment (TME) of papillary thyroid carcinomas (PTCs). However, the characteristic of these tumor-infiltrating lymphocytes (TILs) is not well understood.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>We aim to define the TME of PTC cases by characterizing the TILs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>This is a cross-sectional observational study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients<\/jats:title><jats:p>We enrolled 29 PTC (23 having concurrent LT), 14 LT, and 13 hyperplastic nodules with LT (HN) patients from January 2016 to December 2020.<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements<\/jats:title><jats:p>Immunohistochemical (IHC) expression of CD8, FoxP3, PD-1, and PD-L1 was studied in PTC with LT and compared with HN. PD-1 and PD-L1 expression was correlated at the mRNA level by quantitative real-time PCR. Immunophenotyping of TILs was done in FNAC samples of PTC and LT by flow cytometry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>IHC revealed the presence of CD8<jats:sup>+<\/jats:sup> cytotoxic T lymphocytes (CTLs) and FoxP3<jats:sup>+<\/jats:sup> T regulatory cells (Tregs) in 83% and 52% of PTC with LT cases, respectively. Flow cytometric analysis of the PTC samples revealed a significant abundance of CTL compared with Treg and a higher CTL with lower Treg counts compared with LT. On IHC, PD-1 positivity was noted in 56.5% of PTC with LT cases, while intermediate PD-L1 positivity was found in 70% of the cases. There was a significant upregulation of PD-1 mRNA in PTC with LT. A significant correlation was noted with PD-L1 expression with lymph node metastasis and presence of Treg cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Increased expression of PD-1 and PD-L1 in the TME of PTC may provide a potential molecular mechanism for tumor survival despite the predominance of CTLs, possibly through their inactivation or exhaustion.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.931647","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T05:44:55Z","timestamp":1669614295000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Role of cytotoxic T cells and PD-1 immune checkpoint pathway in papillary thyroid carcinoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Sohini","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Nahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Dahiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soham","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranab","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rijuneeta","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishan","family":"Radotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay Kumar","family":"Bhadada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Bhansali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2008.00908.x","article-title":"Subclassification of non-solid-type papillary thyroid carcinoma identification of high-risk group in common type","volume":"99","author":"Bai","year":"2008","journal-title":"Cancer Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0134","article-title":"BRAFV600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration","volume":"24","author":"Angell","year":"2014","journal-title":"Thyroid"},{"key":"B3","first-page":"24","article-title":"Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma","volume":"5","author":"Russell","year":"2013","journal-title":"Head Neck Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-1","article-title":"The immune score as a new possible approach for the classification of cancer","volume":"10","author":"Galon","year":"2012","journal-title":"J Trans Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/science.342.6165.1432","article-title":"Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Am Assoc Adv Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3463","article-title":"Ipilimumab","volume":"10","author":"Sondak","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015586218","article-title":"Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology","volume":"49","author":"Barbee","year":"2015","journal-title":"Ann Pharmacother"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Hollebecque a et.al. immune-related adverse events with immune checkpoint blockade: A comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/science.275.5302.960","article-title":"Potential involvement of fas and its ligand in the pathogenesis of hashimoto's thyroiditis","volume":"275","author":"Giordano","year":"1997","journal-title":"Science"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2014.12.013","article-title":"PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises","volume":"41","author":"Massari","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2063","article-title":"Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer","volume":"19","author":"Sznol","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-69-4-832","article-title":"Phenotypic and functional analysis at the clonal level of infiltrating T lymphocytes in papillary carcinoma of the thyroid: Prevalence of cytolytic T cells with natural killer-like or lymphokine-activated killer activity","volume":"69","author":"Bagnasco","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13000-017-0662-z","article-title":"PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma","volume":"12","author":"Bai","year":"2017","journal-title":"Diagn Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.21674","article-title":"Distribution of lymphocyte subpopulations in thyroid glands of human autoimmune thyroid disease","volume":"28","author":"Zha","year":"2014","journal-title":"J Clin Lab Analysis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2020-206832","article-title":"PD-L1 expression by tumor proportion score (TPS) and combined positive score (CPS) are similar in non-small cell lung cancer (NSCLC)","volume":"74","author":"De Marchi","year":"2021","journal-title":"J Clin Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-018-2357-6","article-title":"In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related","volume":"472","author":"Bai","year":"2018","journal-title":"Virchows Archiv"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/01.MP.0000096047.99202.31","article-title":"Expression of galectin-3 in normal and malignant thyroid tissue by quantitative PCR and immunohistochemistry","volume":"16","author":"Feilchenfeldt","year":"2003","journal-title":"Modern Pathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-13-0436","article-title":"Lymphocytic profiling in thyroid cancer provides clues for failure of tumor immunity","volume":"21","author":"Imam","year":"2014","journal-title":"Endocrine-related Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12586","article-title":"CD8+ tumour-infiltrating lymphocytes and COX2 expression may predict relapse in differentiated thyroid cancer","volume":"83","author":"Cunha","year":"2015","journal-title":"Clin Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030342","article-title":"Papillary thyroid carcinomas from young adults and children contain a mixture of lymphocytes","volume":"88","author":"Modi","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2019.e03077","article-title":"Hashimoto's thyroiditis attenuates progression of papillary thyroid carcinoma: Deciphering immunological links","volume":"6","author":"Sulaieva","year":"2020","journal-title":"Heliyon"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-012-9853-2","article-title":"Regulatory T cells and plasmacytoid dendritic cells contribute to the immune escape of papillary thyroid cancer coexisting with multinodular non-toxic goiter","volume":"44","author":"Yu","year":"2013","journal-title":"Endocrine"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2012(05)13","article-title":"Foxp3 expression is associated with aggressiveness in differentiated thyroid carcinomas","volume":"67","author":"Cunha","year":"2012","journal-title":"Clinics (Sao Paulo)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1838","article-title":"Phenotypical analysis of lymphocytes with suppressive and regulatory properties (Tregs) and NK cells in the papillary carcinoma of thyroid","volume":"97","author":"Gogali","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-014-1222-6","article-title":"Analysis of regulatory T cells frequency in peripheral blood and tumor tissues in papillary thyroid carcinoma with and without hashimoto\u2019s thyroiditis","volume":"17","author":"Liu","year":"2015","journal-title":"Clin Trans Oncol"},{"key":"B26","article-title":"CD4+ CD25+ T regulatory cells: their physiology and role in modulating immune response","volume":"59","author":"Lewkowicz","year":"2005","journal-title":"Postepyhigieny  Medycynydoswiadczalnej (Online)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-017-0794-8","article-title":"Chronic lymphocytic thyroiditis (CLT) has a positive prognostic value in papillary thyroid cancer (PTC) patients: The potential key role of Foxp3+ T lymphocytes","volume":"41","author":"Pilli","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2012.04482.x","article-title":"Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma","volume":"77","author":"Cunha","year":"2012","journal-title":"Clin Endocrinol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4161\/onci.27926","article-title":"Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy","volume":"3","author":"Issa-Nummer","year":"2014","journal-title":"Oncoimmunology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2564","article-title":"Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer","volume":"95","author":"French","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nri1806","article-title":"Regulatory T cells, tumour immunity and immunotherapy","volume":"6","author":"Zou","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520919222","article-title":"Changes in treg numbers and activity in papillary thyroid carcinoma with and without hashimoto\u2019s thyroiditis","volume":"48","author":"Zhao","year":"2020","journal-title":"J Int Med Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27782","article-title":"CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review","volume":"234","author":"Farhood","year":"2019","journal-title":"J Cell Physiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13000-021-01139-7","article-title":"T Cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis","volume":"16","author":"Zhu","year":"2021","journal-title":"Diagn Pathol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.7421","article-title":"Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: Long-term safety, clinical activity, and immune correlates from a phase ia study","volume":"34","author":"McDermott","year":"2016","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1530\/ERC-16-0421","article-title":"Comprehensive screening for PD-L1 expression in thyroid cancer","volume":"24","author":"Ahn","year":"2017","journal-title":"Endocrine Related Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.117","article-title":"Impact of oncogenic pathways on evasion of antitumour immune responses","volume":"18","author":"Spranger","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-255125","article-title":"Interferon-\u03b3 and tumor necrosis factor-\u03b1 induce an immunoinhibitory molecule, B7-H1, via nuclear factor-\u03baB activation in blasts in myelodysplastic syndromes","volume":"116","author":"Kondo","year":"2010","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000300","article-title":"PD-1\/PD-L1 axis in lung cancer","volume":"24","author":"Santini","year":"2018","journal-title":"Cancer J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4227","article-title":"Tumor-infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer","volume":"101","author":"Bastman","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31661","article-title":"Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma","volume":"143","author":"Harris-Bookman","year":"2018","journal-title":"Int J Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3016","article-title":"IL10 and PD-1 cooperate to limit the activity of tumor-specific CD8+ T cells","volume":"75","author":"Sun","year":"2015","journal-title":"Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/CJI.0000000000000065","article-title":"Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1\/PD-L1 interactions","volume":"38","author":"Lussier","year":"2015","journal-title":"J Immunother"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13102","article-title":"Association between PD-L1 expression and lymph node metastasis in cutaneous squamous cell carcinoma","volume":"16","author":"Kamiya","year":"2020","journal-title":"Asia-Pacific J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01057-7","article-title":"Programmed death ligand 1 (PD-L1) as a predictive biomarker for pembrolizumab therapy in patients with advanced non-small-cell lung cancer (NSCLC)","volume":"36","author":"Incorvaia","year":"2019","journal-title":"Adv Ther"},{"key":"B49","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort a of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1158\/2326-6066.CIR-15-0210","article-title":"PD-1 blockade expands intratumoral memory T cells","volume":"4","author":"Ribas","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42047-019-0033-z","article-title":"Expression of PD-L1 in primary breast carcinoma and lymph node metastases","volume":"2","author":"Alves","year":"2019","journal-title":"Surg Exp Pathol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.10.015","article-title":"Programmed cell death ligand (PD-L1) expression in stage II and III lung adenocarcinomas and nodal metastases","volume":"12","author":"Uruga","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-017-3916-y","article-title":"Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer","volume":"18","author":"Li","year":"2018","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.931647\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T05:44:59Z","timestamp":1669614299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.931647\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":53,"alternative-id":["10.3389\/fendo.2022.931647"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.931647","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,28]]},"article-number":"931647"}}